Overview
Braidwell is a Delaware limited partnership that launched its business in 2021. Alex Karnal
and Brian Kreiter (the “Co-Founders”), as managing members and principal owners of
Braidwell’s general partner, Braidwell Management LLC, control Braidwell. Braidwell is owned
by the Co-Founders (personally or through estate planning and other vehicles established by
or on behalf of any of them and their families). The activities of Braidwell are led by the Co-
Founders together with other professionals who assist in executing Braidwell’s strategies on
behalf of clients (such professionals, together with the Co-Founders, “Braidwell Personnel”).
Braidwell provides discretionary investment advice to pooled investment vehicles
(collectively, the “Funds”). The Funds are managed in accordance with their own investment
objectives, as described in their respective offering documents and governing agreements
(together, the “Governing Documents”). The Funds are generally organized as “master-
feeder” fund structures with multiple feeder funds, master funds, and intermediate blocker
entities. Braidwell GP LLC, a Delaware limited liability company, serves as the general partner
or managing member of the Funds, (the “General Partner”). The General
Partner is an
affiliate of Braidwell and is also controlled by the Co-Founders.
Braidwell was formed with the goal of investing in opportunities in the biological revolution to
transform human health. Braidwell’s philosophy is based on the belief that intrinsic strength
results when multiple components join together to form a greater whole. Braidwell seeks to
employ a team of experts from varied backgrounds that will imaginatively blend diverse
perspectives, integrate disparate strands of information and structure flexible, creative capital
allocations – all to identify, pursue and accelerate what Braidwell believes to be most
promising medical advancements. The Funds’ portfolios are primarily composed of
investment opportunities in biotechnology, pharmaceuticals, medical devices, diagnostics and
other healthcare-related products and businesses.
Braidwell has full investment discretion in investing on behalf of the Funds and is not required
to seek approval from the Funds or the investors in the Funds with respect to the Funds’
investing.
As of the close of business on December 31, 2023, Braidwell advised approximately
$4,902,200,000 in regulatory assets under management on a discretionary basis. Braidwell
does not manage assets on a non-discretionary basis.